MHE August 2023

In an episode of Managed Healthcare Executive’s “Between the Lines” video series, Leslie Cho, M.D., and Seth Shay Martin, M.D., M.H.S., discussed bempedoic acid, the CLEAR Outcomes trial and the implications for cardiovascular disease prevention.

Interoperability has been an aspiration in the healthcare IT world for many years. The finalization of new rules means they finally have a chance to prove its merits.

Ibudilast is a small molecule being developed by biopharmaceutical company MediciNova for the potential treatment of MS. The company, based in La Jolla, California, is currently calling the oral formulation MN-166.

As the Federal Trade Commission weighs a ban, hospitals and some physician organizations are on opposite sides of the issue.

The track record on outsourcing clinical services is mixed.

A discussion with Jeffrey Casberg, M.S., who joined the Managed Healthcare Executive editorial advisory board in July 2023. Casberg is senior vice president of clinical pharmacy at IPD Analytics and has played a leadership role in its drug management strategy business. A pharmacist by training, Casberg has had a long career in managed care.

Medicaid managed care plans will be affected as states shed enrollees because of the end of the continuous enrollment provisions of the COVID-19 public health emergency.

Charging more than $2 million for a single treatment was once unthinkable, but no more.

Recent years have brought a host of new orphan medications for rare disorders, and more are coming. But the U.S. hasn’t yet settled on a way to handle their often astronomical prices — and neither has any other country.

Selective estrogen receptor degraders are vying to join aromatase inhibitors and selective estrogen receptor modulators as therapy after the initial treatment of breast cancer.